Davis Polk and Hogan Lovells advised Precigen on the offering, and Goodwin Procter advised the underwriters involved. Precigen Inc. announced the SEC-registered offering of an aggregate of...
Precigen’s $75 Million Common Stock Offering
URUS’s $170 Million Acquisition of Trans Ova Genetics
Davis Polk advised Precigen on the deal. Precigen, Inc. executed the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal...